Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Grégoire M
Institut National de la Santé et de la Recherche Médicale 419, IFR 26, Biology Institute, Nantes, France.
Cancer Res. 1999 Jul 15;59(14):3329-32.
We have reported recently that treatments combining injections of apoptotic bodies from tumor cells and interleukin 2 led to tumor regression and induced specific protection. In the present study, we show that tumor-bearing rats were cured with an 80% success rate by injection of antigen-presenting cells (APCs) that had phagocytosed apoptotic bodies derived from poorly immunogenic tumor cells, whereas phagocytic cells exposed to nonapoptotic tumor cell extracts were essentially without effect. In addition, curative vaccination using APCs that had phagocytosed apoptotic bodies generated a tumor-specific cytotoxic T-cell response and long-term protection from parental tumor challenge. Thus, systems using the processing and presentation of antigenic molecules by professional APCs after phagocytosis of apoptotic bodies appear to offer new possibilities for anticancer treatment.
我们最近报道,将肿瘤细胞凋亡小体注射与白细胞介素2相结合的治疗方法可导致肿瘤消退并诱导特异性保护。在本研究中,我们发现,通过注射吞噬了低免疫原性肿瘤细胞凋亡小体的抗原呈递细胞(APC),荷瘤大鼠的治愈率达80%,而暴露于非凋亡肿瘤细胞提取物的吞噬细胞基本无效。此外,使用吞噬了凋亡小体的APC进行治愈性疫苗接种可产生肿瘤特异性细胞毒性T细胞反应,并对亲本肿瘤攻击提供长期保护。因此,在吞噬凋亡小体后利用专业APC处理和呈递抗原分子的系统似乎为抗癌治疗提供了新的可能性。